Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

(2020) Manli Wang et al.   CELL RESEARCH

Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia

(2020) Daniel K W Chu et al.   CLINICAL CHEMISTRY

Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore

(2020) Barnaby Edward Young et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

(2020) Stephen A. Lauer et al.   ANNALS OF INTERNAL MEDICINE

The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID‐19

(2020) Virginia D. Schmith et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prioritisation of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics

(2020) Usman Arshad et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A review on possible modes of actions of Chloroquine/ Hydroxychloroquine: Repurposing against SAR-COV-2 (COVID 19) pandemic

(2020) Satyajit Tripathy et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

(2020) Philippe Gautret et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

(2020) Wenling Wang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)

(2020) James M. Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

(2020) Kelvin Kai-Wang To et al.   LANCET INFECTIOUS DISEASES

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

(2020) David E. Gordon et al.   NATURE

Antibody responses to SARS-CoV-2 in patients with COVID-19

(2020) Quan-Xin Long et al.   NATURE MEDICINE

Remdesivir for the Treatment of Covid-19 — Preliminary Report

(2020) John H. Beigel et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

(2020) Bin Cao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

(2020) Yan Zhang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

(2020) Wei Tang et al.   BMJ-British Medical Journal

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China

(2020) Ling Mao et al.   JAMA Neurology

Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues

(2020) Meng-Yuan Li et al.   Infectious Diseases of Poverty

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

(2020) Jia Liu et al.   Cell Discovery

Potential role for nitazoxanide in treating SARS-CoV-2 infection

(2020) Paulo Ricardo Martins-Filho et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

Ivermectin and COVID-19: A report in Antiviral Research, widespread interest, an FDA warning, two letters to the editor and the authors' responses

(2020) Mike Bray et al.   ANTIVIRAL RESEARCH

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

(2020) Leon Caly et al.   ANTIVIRAL RESEARCH

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

(2020) Ka-Tim Choy et al.   ANTIVIRAL RESEARCH

Impact of SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients with Coronavirus Disease 2019

(2020) Reed Magleby et al.   CLINICAL INFECTIOUS DISEASES

Antimalarial-agent artemisinin and derivatives portray more potent binding to Lys353 and Lys31-binding hotspots of SARS-CoV-2 spike protein than hydroxychloroquine: potential repurposing of artenimol for COVID-19

(2020) Moussa Sehailia et al.   JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

(2020) J.M. Molina et al.   MEDECINE ET MALADIES INFECTIEUSES

Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2

(2020) Markus Hoffmann et al.   NATURE

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

(2020) David R. Boulware et al.   NEW ENGLAND JOURNAL OF MEDICINE

The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?

(2020) Eugenia Quiros Roldan et al.   PHARMACOLOGICAL RESEARCH

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

(2020) F.A. Klok et al.   THROMBOSIS RESEARCH

COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted?

(2020) Eddy Fan et al.   Lancet Respiratory Medicine

Anti-SARS-CoV-2 Potential of Artemisinins In Vitro

(2020) Ruiyuan Cao et al.   ACS Infectious Diseases

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

(2020) Yujun Tang et al.   Frontiers in Immunology

In-host Mathematical Modelling of COVID-19 in Humans

(2020) Esteban A. Hernandez-Vargas et al.   ANNUAL REVIEWS IN CONTROL

Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial

(2020) Radha Rajasingham et al.   CLINICAL INFECTIOUS DISEASES

SARS-CoV-2 detection, viral load and infectivity over the course of an infection

(2020) Kieran A. Walsh et al.   JOURNAL OF INFECTION

Hydroxychloroquine in hospitalized COVID‐19 patients: Real world experience assessing mortality

(2020) Frank H. Annie et al.   PHARMACOTHERAPY

COVID-19 and the rush for self-medication and self-dosing with ivermectin: A word of caution

(2020) Marcelo Beltrão Molento   One Health

The effect of food on the pharmacokinetics of oral ivermectin

(2019) Urs Duthaler et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Serious Neurological Adverse Events after Ivermectin—Do They Occur beyond the Indication of Onchocerciasis?

(2018) Rebecca E. Chandler   AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE

Nicotine and the Renin-Angiotensin System

(2018) Joshua M. Oakes et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety

(2017) Carlos Chaccour et al.   MALARIA JOURNAL

Trapping of ivermectin by a pentameric ligand-gated ion channel upon open-to-closed isomerization

(2017) Nurit Degani-Katzav et al.   Scientific Reports

Population pharmacokinetic properties of artemisinin in healthy male Vietnamese volunteers

(2016) Sofia Birgersson et al.   MALARIA JOURNAL

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review

(2016) Jonathan Shuter   Therapeutics and Clinical Risk Management

Viral kinetic modeling: state of the art

(2014) Laetitia Canini et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus

(2012) Kylie M. Wagstaff et al.   BIOCHEMICAL JOURNAL

Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug

(2012) E. Mastrangelo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Sequential Population Pharmacokinetic Modeling of Lopinavir and Ritonavir in Healthy Volunteers and Assessment of Different Dosing Strategies

(2011) Laura Dickinson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges ahead

(2011) Catherine AA Beauchemin et al.   BMC PUBLIC HEALTH

Pharmacokinetics of Hydroxychloroquine and Its Clinical Implications in Chemoprophylaxis against Malaria Caused by Plasmodium vivax

(2009) H.-S. Lim et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Bioavailability of two oral formulations of a single dose of levofloxacin 500 mg: An open-label, randomized, two-period crossover comparison in healthy mexican volunteers

(2009) Juan Francisco Galan-Herrera et al.   CLINICAL THERAPEUTICS